

YCharOS adds ABclonal Technology to Industry Advisory Committee

YCharOS continues to expand Industry Advisory Committee and releases new open data

TORONTO, CANADA, March 21, 2022 /EINPresswire.com/ -- [YCharOS Inc.](#), an open science company with the mission of characterizing commercially available antibody reagents for all human proteins, is pleased to announce the continued expansion of its Industry Advisory Committee (IAC).

Further supporting YCharOS's purpose, leading antibody manufacturer ABclonal Technology has joined the

IAC, alongside antibody and cell line providers Abcam, Aviva Systems Biology, Bio-Techne, GeneTex, Horizon Discovery (a PerkinElmer Company), Institute for Protein Innovation (IPI), Proteintech, Synaptic Systems and Thermo Fisher Scientific.

The role of the IAC is to support YCharOS in enabling users of antibodies, grant funders and the broader scientific community to better evaluate commercially available antibody reagents and associated knockout cell lines. The IAC will help guide the YCharOS team to become the world's premier source for independent, open-source antibody characterization data.

In addition, YCharOS is announcing the release of new open science data. The current results, for antibodies targeting 41 proteins of relevance to neurology and pharmacology, have been posted to Zenodo, the open science platform run by [CERN](#). Antibodies have been tested for Western blot (WB), immunoprecipitation (IP) and immunofluorescence (IF) applications.

"The addition of ABclonal Technology to the IAC further strengthens the quality of the data we produce," said YCharOS Board Chair Dr. Aled Edwards. "They are a tremendous addition to our committee of high-quality manufacturers."



“The addition of ABclonal is further validation of our business model and the value we bring to our partner companies,” said YCharOS CEO Chetan Raina. “Partnering with YCharOS is a strong signal to the marketplace and the research community of their commitment to generate and sell the highest quality products.”

Finding the right antibody for an experiment is a significant challenge for researchers and sits at the heart of the reproducibility crisis observed in biomedical research. To address this unmet need, YCharOS is performing head-to-head comparisons of commercially available antibodies to the same target protein and publishing the results in a transparent and open access way.

Companies or researchers interested in supporting our work are encouraged to contact YCharOS.

ABclonal Technology: www.abclonal.com/

Abcam: www.abcamplc.com

Aviva Systems Biology: www.avivasysbio.com

Bio-Techne: www.bio-techne.com

GeneTex: www.genetex.com

Horizon Discovery: www.horizondiscovery.com

Institute for Protein Innovation (IPI): www.proteininnovation.org

Proteintech: www.ptglab.com

Synaptic Systems: www.sysy.com

Thermo Fisher Scientific: www.thermofisher.com

Notes to Editors

About YCharOS Inc.

YCharOS Inc. (Antibody Characterization through Open Science) is a Canadian, public interest, open science company with the mission of characterizing commercially available antibody reagents for all human proteins. All of YCharOS's scientific methods and results are transparent and patent-free. The antibody characterization platform industrializes the [rigorous methodology](#) established at the Montreal Neurological Institute at McGill University, in collaboration with the Structural Genomics Consortium. The company is wholly owned by the Agora Open Science Trust, a registered charity.

For more information, see www.ycharos.com.

Chetan Raina

YCharOS Inc.

+1 917-509-8295

[email us here](#)

Visit us on social media:

[Twitter](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/565880104>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.